iShares U.S. Healthcare ETF News - May 29, 2026
Bristol Myers Squibb Cuts Multiple Myeloma Risk 52%, Validating New Drug Class
Bristol Myers Squibb announced positive results from the Phase 3 SUCCESSOR-2 trial for mezigdomide. The study evaluated the treatment for patients with...
Johnson & Johnson Wins FDA Approval for TREMFYA to Prevent Joint Damage
Johnson & Johnson received FDA approval for a supplemental Biologics License Application for its drug TREMFYA (guselkumab). The expanded label includes...
Eli Lilly Hits Record High, Securing Key CVS Obesity Drug Coverage
CVS Caremark will add Eli Lilly’s new oral obesity pill, Foundayo, to its formulary. The pharmacy benefit manager (PBM) also restored coverage for the...